Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $40.5556.

A number of research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Oppenheimer upped their price objective on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday. Finally, Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th.

Pharvaris Stock Down 1.4%

Shares of NASDAQ PHVS opened at $27.59 on Thursday. The company has a market capitalization of $1.46 billion, a PE ratio of -8.59 and a beta of -2.79. The stock’s 50 day moving average price is $25.79 and its 200-day moving average price is $23.79. Pharvaris has a twelve month low of $11.51 and a twelve month high of $29.80.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, research analysts expect that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently modified their holdings of the business. Palumbo Wealth Management LLC lifted its stake in shares of Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after buying an additional 447 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock worth $1,751,000 after acquiring an additional 21,388 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in shares of Pharvaris in the second quarter worth $57,000. Geode Capital Management LLC boosted its holdings in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.